Convalescent plasma therapy in COVID-19 critically ill patients during advanced phases of clinical trials and their preliminary results.

Publisher: Instituto de Ensino e Pesquisa Albert Einstein Country of Publication: Brazil NLM ID: 101281800 Publication Model: eCollection Cited Medium: Internet ISSN: 2317-6385 (Electronic) Linking ISSN: 16794508 NLM ISO Abbreviation: Einstein (Sao Paulo) Subsets: MEDLINE

Original Publication: São Paulo, SP : Instituto de Ensino e Pesquisa Albert Einstein

COVID-19*/therapy; Critical Illness ; Humans ; Immunization, Passive ; Multicenter Studies as Topic ; Plasma ; SARS-CoV-2 ; Treatment Outcome ; COVID-19 Serotherapy

The objective of this study was to highlight the global scientific effort to fight the SARS-CoV-2, addressing the preliminary results of passive immunization through convalescent plasma. We performed a search at the major databases of interventional clinical trial protocols about the transfusion of convalescent plasma in patients with COVID-19, as well as, published articles (n≥25), using the following search strategy: [(COVID-19 OR SARS-CoV-2 OR nCoV-2019) AND (Convalescent plasma OR Plasma exchange) AND (Treatment OR Therapy)]. A total of 24 interventional clinical trial protocols (advanced in phases II-III, III, and IV) were included in this review, as well as three studies that had enough outcomes to evaluate the efficacy of convalescent plasma therapy for patients with COVID-19. All interventional clinical trial protocols applied approximately 500mL of convalescent plasma (from single or more donations) in hospitalized patients, mainly in patients with severe disease associated with standard therapy for COVID-19, and compared to placebo or standard therapy plus specific drugs. Most of interventional clinical trial protocols are multicenter, and the phase IV studies are recruiting at intercontinental centers of North America, Oceania, Europe, but most are recruiting center inside their own county. The three studies published reported similar approach of convalescent plasma intervention with decrease in length of stay, mortality, with less than 4% of adverse events, mainly for treating critical cases with life-threatening disease. All advanced clinical trials focused on convalescent plasma therapy in patients with COVID-19 hospitalized in severe conditions, and the preliminary results provide strong evidence for therapy for the COVID-19 patients.

N Engl J Med. 2021 Feb 25;384(8):693-704. (PMID: 32678530)
Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6. (PMID: 15616839)
Cochrane Database Syst Rev. 2020 May 14;5:CD013600. (PMID: 32406927)
Rev Invest Clin. 2020;72(3):159-164. (PMID: 32584322)
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1011-1019. (PMID: 32291542)
Transfus Apher Sci. 2020 Oct;59(5):102875. (PMID: 32694043)
Transfus Apher Sci. 2020 Oct;59(5):102867. (PMID: 32620409)
J Infect Dis. 2020 Jun 16;222(1):38-43. (PMID: 32348485)
J Clin Invest. 2020 Apr 1;130(4):1545-1548. (PMID: 32167489)
BMJ. 2020 Sep 15;370:m3516. (PMID: 32933945)
JAMA. 2020 Aug 4;324(5):460-470. (PMID: 32492084)
N Engl J Med. 2007 Oct 4;357(14):1450-1. (PMID: 17914053)
Vaccines (Basel). 2020 Aug 25;8(3):. (PMID: 32854391)
J Clin Invest. 2020 Sep 1;130(9):4791-4797. (PMID: 32525844)
Blood. 2020 Aug 6;136(6):755-759. (PMID: 32573724)
Clin Infect Dis. 2011 Feb 15;52(4):447-56. (PMID: 21248066)
Science. 2020 May 15;368(6492):699. (PMID: 32409456)
Am J Pathol. 2020 Aug;190(8):1680-1690. (PMID: 32473109)
Vox Sang. 2020 Oct;115(7):545-547. (PMID: 32240549)
BMJ. 2009 Jul 21;339:b2535. (PMID: 19622551)
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. (PMID: 32253318)

Date Created: 20210422 Date Completed: 20210426 Latest Revision: 20221207

20231215

PMC8034864

10.31744/einstein_journal/2021RW6186

33886937